SCHEMBL31052458

SCHEMBL31052458

COc1ccc(F)c(NC(=O)c2cnc(Br)s2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNQ3 O43525 1/20 0.42
▸ KCNQ2 O43526 1/20 0.42
▸ PDE4D Q08499 7/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KCNMA1 Q12791 1/20 0.38
▸ PDE4A P27815 3/20 0.38
▸ PDE4B Q07343 3/20 0.38
▸ PDE4C Q08493 3/20 0.38
▸ MAPT P10636 4/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ GRM4 Q14833 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31052656 0.84 PDE4D (0.41) PDE4DKMT2APOLBMEN1MAPT
SCHEMBL31052481 0.78 LCK (0.42) NPC1RAB9A
SCHEMBL31052554 0.77 LCK (0.41) KMT2APOLBMEN1MAPT
SCHEMBL31052425 0.77 LCK (0.44) KMT2APOLBMEN1MAPTNPC1
SCHEMBL16321002 0.77 IL2 (0.42) KMT2ASMN1; SMN2
SCHEMBL31052487 0.71 MAPK14 (0.41) —
SCHEMBL31727725 0.70 LCK (0.46) PDE4DKMT2APOLBMEN1
SCHEMBL31052638 0.70 MAPK14 (0.43) —
SCHEMBL1539936 0.69 MAPK14 (0.69) —
SCHEMBL31052681 0.69 LCK (0.60) LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676923-A1 BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS Cancer Research Technology Limited (GB) 2026-01-14 — — EP disclosed
WO-2024184550-A1 BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-09-12 — — WO disclosed
Send feedback